Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor ligand superfamily member 12 (TWEAK)
- Target
- TWEAK
- Molecular classification
- Cytokine, Tumor Necrosis Factor Ligand Superfamily
01
Overview
TNFSF12, also known as TWEAK, is a cytokine belonging to the tumor necrosis factor (TNF) ligand superfamily. It exists in both membrane-bound and secreted forms. It primarily binds to the FN14/TWEAKR receptor. TWEAK has several key biological activities including induction of apoptosis, promoting angiogenesis, and mediating activation of the NF-kappa-B signaling pathway. Excessive activation of the TWEAK/FN14 pathway has been implicated in pathological tissue changes during chronic injury, such as chronic inflammation and fibrosis.
- Other names
- TWEAKAPO3 ligandDR3LGAPO3LTNF-related weak inducer of apoptosis
02
Biological functions
ApoptosisAngiogenesisInflammationNF-kappa-B signaling pathwayImmune regulation
03
Disease associations
Chronic inflammationFibrosisImmunodeficiency disordersAmnestic disorderChronic liver diseasePathological angiogenesis
04
Safety considerations
Excessive activation in chronic injuryPotential to exacerbate chronic inflammatory diseases
Beyond the preview
Go deeper on Tumor necrosis factor ligand superfamily member 12 (TWEAK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor necrosis factor ligand superfamily member 12 (TWEAK).